Alessandro Cuttone

Dr. Alessandro Cuttone

University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Cells
Verified
Journal Article
Open access
PDF file
ACAlessandro Cuttone
Alessandro Cuttone
VCVittorio Cannavó
Vittorio Cannavó
AAAbdul Raouf Mastan Sheik Abdullah
Abdul Raouf Mastan Sheik Abdullah
PFPierluigi Fugazzotto
Pierluigi Fugazzotto
GAGiada Arena
Giada Arena
Giuseppina Tiziana RussoGiuseppina Tiziana Russo
Giuseppina Tiziana Russo
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are currently recommended in patients with type 2 diabetes (T2D) to reduce serum glucose levels. Moreover, robust evidence has clearly demonstrated their beneficial cardiovascular and renal effects, making this class of drugs pivotal for the treatment of T2D, especially when complicated by diabetic kidney disease or heart failure. However, several other comorbidities are frequently encountered in T2D patients beyond these long-term diabetes complications, especially in the internal medicine setting. For some of these comorbidities, such as MAFLD and cognitive impairment, the association with diabetes is increasingly recognized, with the hypothesis of a common pathophysiologic background, whereas, for others, a coincident epidemiology linked to the ageing of populations, including that of T2D subjects, may be advocated. In the effort of personalizing T2D treatment, evidence on the potential effects of SGLT2i in these different clinical conditions is accumulating. The purpose of this narrative review is to update current literature on the effects of SGLT2i for the treatment of T2D in different clinical settings beyond glycaemic control, and to elucidate potential molecular mechanisms by which they exert these effects.

AGAnnalisa Giandalia
Annalisa Giandalia
MRMarta Ragonese
Marta Ragonese
EAEugenio Alessi
Eugenio Alessi
MRMaria C. Ruffo
Maria C. Ruffo
Alberto SardellaAlberto Sardella
Alberto Sardella
Giuseppina Tiziana RussoGiuseppina Tiziana Russo
Giuseppina Tiziana Russo
Background: The Locus of Control (LOC) is a mental disposition indicating the individuals’ belief that disease-related outcomes are under their own control (Internal), dependent on others (External), or dependent on chance (Chance). Quality of Life (QoL) and LOC may have complex effects on self-care activities and diabetes management in subjects with type 2 diabetes (T2D). The aim of the present study was to evaluate the predictive role of LOC and QoL scores on metabolic control in elderly T2D outpatients, secondly evaluating potential gender differences. Methods: An extensive set of questionnaires was administered to a group of consecutive elderly T2D outpatients on oral glucose-lowering drugs attending a single diabetes center. Personal and clinical variables were analyzed at baseline (between 1 February and 31 March 2015) and after 6 years of follow-up. Results: At baseline, study participants showed an overall good metabolic control. Diabetes Specific Quality of Life (DSQoL) scores indicated an overall good QoL in both genders, with a higher DSQoL satisfaction score in women. Both genders presented higher scores in the LOC-Internal domain, with men reaching higher scores in the LOC-External domain than women. At the 6-years follow-up, subjects with baseline higher LOC-External score presented better metabolic outcome. In the regression analysis, LOC-External score was an independent predictor of good metabolic control maintenance, but this result was only statistically significant in men. Conclusions: LOC scores may influence long-term glycemic control in elderly T2D patients on oral glucose-lowering drugs.

15 May 2025 in Cells
Verified
Journal Article
Open access
ACAlessandro Cuttone
Alessandro Cuttone
AXAnastasia Xourafa
Anastasia Xourafa
CMCarmela Morace
Carmela Morace
VCVittorio Cannavó
Vittorio Cannavó
FBFrancesca Maria Bueti
Francesca Maria Bueti
FBFederica Bellone
Federica Bellone
Diabetes mellitus has been knowingly associated with increased risk of fractures, so much so that skeletal fragility is considered a complication of diabetes. Determinants of bone fragility in this chronic condition are several, and the diabetes treatment choice could influence bone metabolism. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently expanded the therapeutic armamentarium for type 2 diabetes mellitus (T2D); these antihyperglycemic drugs act by reducing renal glucose reabsorption in the proximal tubule and have a proven cardiorenal benefit. The role of SGLT2i towards phospho-calcium metabolism is still unclear, so we aimed to review the current evidence of the relationship between SGLT2i and calcium and phosphate homeostasis. The PubMed, Scopus, and Web of Knowledge databases were searched to identify original research articles, meta-analyses, and scientific reviews on effects on bone metabolism in T2D patients treated with SGLT2i. Emerging data indicate that SGLT2i may lead to a rise of bone turnover markers, promoting a lower skeletal bone density and an increased fracture risk on murine models, but in real-world studies, results are controversial. Therefore, more clinical trials are needed to further clarify this topic, and the effects of SGLT2i on calcium homeostasis remain to date poorly understood.

18 May 2023 in L'Endocrinologo
Verified
Journal Article
Open access
PDF file
AGAnnalisa Giandalia
Annalisa Giandalia
ACAlessandro Cuttone
Alessandro Cuttone